- Home
- SCNX vs MRSN Comparison
SCNX vs MRSN Comparison
Compare SCNX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- MRSN
- Stock Information
- Founded
- SCNX 2010
- MRSN 2001
- Country
- SCNX United States
- MRSN United States
- Employees
- SCNX N/A
- MRSN N/A
- Industry
- SCNX Other Pharmaceuticals
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- MRSN Health Care
- Exchange
- SCNX Nasdaq
- MRSN Nasdaq
- Market Cap
- SCNX 65.4M
- MRSN 74.8M
- IPO Year
- SCNX 2020
- MRSN 2017
- Fundamental
- Price
- SCNX $3.90
- MRSN $0.64
- Analyst Decision
- SCNX
- MRSN Buy
- Analyst Count
- SCNX 0
- MRSN 6
- Target Price
- SCNX N/A
- MRSN $6.00
- AVG Volume (30 Days)
- SCNX 10.8K
- MRSN 9.5M
- Earning Date
- SCNX 02-10-2025
- MRSN 02-26-2025
- Dividend Yield
- SCNX N/A
- MRSN N/A
- EPS Growth
- SCNX N/A
- MRSN N/A
- EPS
- SCNX 3.55
- MRSN N/A
- Revenue
- SCNX N/A
- MRSN $34,837,000.00
- Revenue This Year
- SCNX $1,085.75
- MRSN N/A
- Revenue Next Year
- SCNX N/A
- MRSN N/A
- P/E Ratio
- SCNX $1.68
- MRSN N/A
- Revenue Growth
- SCNX 166.67
- MRSN N/A
- 52 Week Low
- SCNX $3.48
- MRSN $0.49
- 52 Week High
- SCNX $44.56
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- MRSN 31.06
- Support Level
- SCNX N/A
- MRSN $0.49
- Resistance Level
- SCNX N/A
- MRSN $0.69
- Average True Range (ATR)
- SCNX 0.00
- MRSN 0.11
- MACD
- SCNX 0.00
- MRSN 0.03
- Stochastic Oscillator
- SCNX 0.00
- MRSN 23.16
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.